2000至2021年荷兰结直肠癌发病率、治疗与相对生存趋势
基于荷兰癌症登记处2000至2021年诊断为结直肠癌的2 75667例患者,按病变范围与部位分层,采用连接点回归分析发病率、治疗与相对生存趋势。结直肠癌发病率升至2010年代中期后大幅下降至与2000年代初相当水平;局限期和区域期结直肠癌五年相对生存持续改善,而远处转移期结直肠癌五年相对生存停滞。
要点
- 局限期结肠癌局部切除率2021年为13.6%,直肠癌为34.9%。
- 远处转移期结肠癌原发肿瘤切除率2000至2021年由60.9%降至12.5%,直肠癌由47.8%降至6.9%。
- 远处转移期结肠癌和直肠癌抗癌治疗率下降,五年相对生存改善停滞。
核心结论
- 2000至2021年荷兰结直肠癌发病率和治疗发生重大变化并被量化;局限期和区域期结直肠癌五年相对生存持续改善,而远处转移期结直肠癌五年相对生存停滞,可能由该组抗癌治疗率下降所致。
研究设计与样本
- 基于荷兰癌症登记处2000至2021年诊断为结直肠癌的2 75667例患者,按病变范围(局限期:T1-3N0M0;区域期:T4N0M0/T1-4N1-2M0;远处转移期:T1-4N0-2M1)和部位(结肠;直肠)分层,采用连接点回归分析趋势。
主要发现
- 结直肠癌发病率升至2010年代中期后大幅下降至与2000年代初相当水平。
- 局限期结肠癌局部切除率2021年为13.6%,直肠癌为34.9%。
- 远处转移期结肠癌原发肿瘤切除率2000至2021年由60.9%降至12.5%,直肠癌由47.8%降至6.9%,同时转移灶局部治疗率增加。
- 局限期和区域期结肠癌五年相对生存2017年分别为97.7%和72.0%,直肠癌分别为95.2%和76.3%。
- 远处转移期结肠癌抗癌治疗率2010至2021年由80.3%降至67.2%(p < 0.001),直肠癌2011至2021年由86.0%降至77.0%(p < 0.001)。
关键数值与推荐
- 远处转移期结肠癌五年相对生存2010至2017年由11.2%升至11.9%,平均年度变化百分比(APC)为2.1(95%CI:-7.6,4.7)。
- 远处转移期直肠癌五年相对生存2009至2017年由12.7%升至15.6%,APC为1.4(95%CI:-19.1,5.5)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The epidemiology of colorectal cancer (CRC) has changed rapidly over the years. The aim of this study was to assess the trends in incidence, treatment, and relative survival (RS) of patients diagnosed with CRC in the Netherlands between 2000 and 2021. PATIENTS AND METHODS: 2 75667 patients diagnosed with CRC between 2000 and 2021 were included from the Netherlands Cancer Registry. Analyses were stratified for disease extent (localised: T1-3N0M0; regional: T4N0M0/T1-4N1-2M0; distant: T1-4N0-2M1) and localisation (colon; rectum). Trends were assessed with joinpoint regression. RESULTS: CRC incidence increased until the mid-2010s but decreased strongly thereafter to rates comparable with the early 2000s. Amongst other trend changes, local excision rates increased for patients with localised colon (2021: 13.6 %) and rectal cancer (2021: 34.9 %). Moreover, primary tumour resection became less common in patients with distant colon (2000-2021: 60.9-12.5 %) or rectal cancer (2000-2021: 47.8-6.9 %), while local treatment of metastases rates increased. Five-year RS improved continuously for localised and regional colon (97.7 % and 72.0 % in 2017, respectively) and rectal cancer (95.2 % and 76.3 % in 2017, respectively). The rate of anti-cancer treatments decreased in distant colon (2010-2021: 80.3 % to 67.2 %; p < 0.001) and rectal cancer (2011-2021: 86.0 % to 77.0 %; p < 0.001). The improvement of five-year RS stagnated for distant colon (2010-2017: 11.2 % to 11.9 %; average percentage of change [APC]: 2.1, 95 % confidence interval [CI]: -7.6, 4.7) and rectal cancer (2009-2017: 12.7 % to 15.6 %; APC: 1.4, 95 % CI: -19.1, 5.5). CONCLUSIONS: Major changes in the incidence and treatment of CRC between 2000 and 2021 were identified and quantified. Five-year RS increased continuously for patients with localised and regional CRC, but stagnated for patients with distant CRC, likely caused by decreased rates of anti-cancer treatment in this group.
引用
- Swartjes H, Sijtsma FPC, Elferink MAG, et al. Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021. Eur J Cancer. 2024. PMID: 38733716. doi:10.1016/j.ejca.2024.114104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。